GLP-1 patches and the transdermal delivery record

What is actually being tested in people

A flat no would be wrong here. Getting a GLP-1 through skin is a live research program with two registered human trials, both started in 2026. Saying so is the difference between a record and a rebuttal.

A microneedle array is not the patch being sold

Both studies use a microneedle array: a small bed of needles that punctures the outer layer of skin and drops the drug underneath. That gets past the skin barrier by making holes in it. A sticker that relies on a molecule drifting through skin on its own is a completely different proposition. Both trials are Phase 1 and still recruiting, with no results posted to ClinicalTrials.gov.

In a company announcement, Daewoong said a separate 70-person human pilot measured how much drug reached the blood. That does not show weight-loss efficacy or turn an online sticker into semaglutide. Read the sponsor announcement.

The lab work points the same way. A 2026 study of a dissolving microneedle system for semaglutide tested insertion on pig skin in a lab model. Its authors say stability and loss of potency are still unsolved. Searches for a registered human study of transdermal tirzepatide, transdermal liraglutide or an exenatide patch returned nothing on 2026-08-12 — the exact searches were “transdermal tirzepatide”, “transdermal liraglutide”, “transdermal patch exenatide”.

The patches sold online are a different category of thing

Patches sold as GLP-1 patches are sold as dietary supplements, not drugs, which is how they reach the market without approval. There is a catch, and it is written into the law rather than a matter of opinion: a dietary supplement is legally defined as something you swallow. A patch is worn, not swallowed — so the category these products claim is not open to them.

A 2026 review in Annals of Pharmacotherapy made that argument and counted the market on the way past. It found 24 patch products and one gel, averaging seven plant ingredients each. The usual ones were berberine, glutamine or glutamate, cinnamon and pomegranate.

None posted a certificate of analysis, many were missing the required disclaimer, and many advertised deceptively. That is not a GLP-1 drug. It is a botanical patch borrowing the name of one.

What the ones on sale actually say they contain

We opened every patch listing we could find and copied down what each one states. Two different products turn out to be sold under one name, which is the single most useful thing to know before reading any review.

Of the 10 listings read on 2026-08-13, only 2 publish an ingredient list at all. On 2026-03-31 the FDA wrote to a seller of one of the microneedle patches and called it an unapproved new drug. The brand-by-brand detail, with each seller’s own wording, is in the patch brand register.

Peptides this size have been tried before

The size argument above is a pattern, not a law. So the fairer test is what happened when drug companies actually tried. 15 human trials have put a peptide into a skin patch, across 6 molecules, going back to 2007.

The closest comparison is teriparatide. It weighs 4,118 g/mol against semaglutide’s 4,113.58. Similar molecular weight does not mean similar absorption. A teriparatide trial reported smaller changes in its main treatment outcome with the patches than with the injection.

A different peptide, abaloparatide, reached phase 3. Its patch group had a smaller change in bone mineral density than the injection group. These results do not show how much drug crossed the skin. The FDA records checked here list neither molecule as an approved patch. The trial outcomes and their units are in the microneedle trial record.

Side effects, and why the safety database is empty

People search for GLP-1 patch side effects expecting the answer that comes with a real medicine. There is no such list, and the reason is worth understanding before you read reassurance into it.

The searches run on August 13, 2026 found no reports under the patch names shown below. That does not establish safety or prove that no reports exist under other names. FDA receives drug reports from manufacturers, healthcare professionals and consumers. A product bought online is not automatically excluded. A report may be missing, incomplete or filed under a different name; the zero counts do not tell us which explanation applies.

Skin irritation is one possible concern, but it is not the only safety question. The searches above cannot establish a product’s ingredients, absorption or rate of adverse effects.

How people are told to use them

A lot of searches ask where to put a patch and how long to wear it. Here is what the sellers themselves say, reported because it is what they say — not because following it achieves anything.

• Most berberine listings say to wear one patch for up to 8 hours, then throw it away. A few say 8 to 12 hours.
• Placement advice is generally clean, dry, hair-free skin, rotating the spot each day. Upper arm, hip, shoulder and abdomen all appear.
• The microneedle listings differ: at least 4 hours, once or twice a week rather than daily.
• One listing gives a wear time of 8 hours in one place and 24 hours in another, on the same page.

None of that is our instruction, and none of it is a dose. Where you stick a patch cannot fix the problem that the molecule it is named after does not cross skin.

What they cost, and where they are sold

Listed prices run from about $12 to $40 a month for the berberine stickers, and roughly $16 to $77 for the microneedle ones. Amazon carries berberine patches from several brands. We could not check Walmart, CVS or Costco, because all three refused an automated request — so whether they stock any of this is unproven rather than ruled out.

For what the real drugs cost, including which savings programs exclude Medicare and Medicaid, see the cost records.